Triazolopyridine cannabinoid receptor 1 antagonists

Details Triazolopyridine cannabinoid receptor 1 antagonists Triazolopyridine cannabinoid receptor 1 antagonists

2006-06-16

2009-08-11

Andres, Janet L. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S119000

Reexamination Certificate

active

07572808

ABSTRACT:
The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula:including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4and R5are described herein.

REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4379785 (1983-04-01), Weyer et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4639436 (1987-01-01), Junge et al.
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4904769 (1990-02-01), Rauenbusch
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbuer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5447954 (1995-09-01), Gribble et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5698527 (1997-12-01), Kim
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5990109 (1999-11-01), Chen et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6184231 (2001-02-01), Hewawasam et al.
patent: 6414002 (2002-07-01), Cheng et al.
patent: 6635626 (2003-10-01), Barrish et al.
patent: 196 22 222 (1997-12-01), None
patent: 0 142 146 (1985-05-01), None
patent: 0 221 025 (1987-05-01), None
patent: 0 675 714 (1995-10-01), None
patent: 1 022 272 (1997-07-01), None
patent: 0 818 448 (1998-01-01), None
patent: 0 992 496 (2005-08-01), None
patent: 2 596 393 (1987-10-01), None
patent: 2 205 837 (1988-12-01), None
patent: 2 304 106 (1997-03-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO93/14091 (1993-07-01), None
patent: WO 94/15592 (1994-07-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 97/35576 (1997-10-01), None
patent: WO 97/48701 (1997-12-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/15201 (2000-03-01), None
patent: WO 00/30665 (2000-06-01), None
patent: WO 00/38722 (2000-07-01), None
patent: WO 00/39077 (2000-07-01), None
patent: WO 00/50574 (2000-08-01), None
patent: WO2004/026301 (2004-04-01), None
patent: WO 2005/037197 (2005-04-01), None
patent: WO 2005/041663 (2005-05-01), None
Yurugi et. al., “Studies on the syntheses of N-Heterocyclic compounds”, Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, May 1973;93 (5): 642-7.
Antel et. al., “CB1 Cannabinoid Receptor Antagonists for Treatment of Obesity and Prevention of Comorbid Metabolic Disorders”, Antel et al., J. Med. Chem. 2006, 49, 4008-4016.
Hcaplus 143:243137.
Hertzog, Donald, Recent Advances in the Cannabinoids, Expert Opin. Ther. Patetns (2004) 14(10):1435-1452.
Hertzog, Donald, Recent Advances in the Cannabinoids, “Expert Opin. Ther. Patents” (2004) 14(10);1435-1452.
Maldonado et. al., “Involvement of the endocannabinoid system in drug addiction”, Trends in Neurosciences, vol. 29, No. 4, Apr. 2006.
J. Lange et al., Journal of Medicinal Chemistry, vol. 27, pp. 627-643, 2004.
U. Pagotto et al., Endocrine Reviews, vol. 27, No. 1, pp. 73-100, 2008.
J. Mussinu et al., Bioorganic & Medicinal Chemistry, vol. 11, pp. 251-263, 2003.
J. Lange et al., Journal of Medicinal Chemistry, vol. 48, pp. 1823-1838, 2005.
M. Krishnamurthy et al., Bioorganic & Medicinal Chemistry, vol. 12, pp. 393-404, 2004.
J. Wiley et al., British Journal of Pharmacology, vol. 145, pp. 293-300, 2005.
R. Katoch-Rouse et al., Journal of Medicinal Chemistry, vol. 46, pp. 642-645, 2003.
Aranyos, A. et al., “Novel Electron-Rich Bulky Phosphine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers”, J. Am. Chem. Soc., vol. 121, pp. 4369-4378 (1999).
Bakke, Jan M., “Nitropyridines: Synthesis and reactions”, Pure Appl. Chem., vol. 75(10), pp. 1403-1415 (2003).
Barder, T. et al., “Catalysts for Suzuki-Miyaura Coupling Processes: Scope and Studies of the Effect of Ligand Structure”, J. Am. Chem. Soc., vol. 127, pp. 4685-4696 (2005).
Biller, S. et al., “Isoprenoid (Phosphinylmethyl) phosphonates as Inhibitors of Squalene Synthetase”, J. of Med. Chem., vol. 31 (10), pp. 1869-1871 (1988).
Biller, S. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, pp. 1-40 (1996).
Bobbio, C. et al., “Selective Functionalization of 2-Fluoropyridine, 2,3-Difluoropyridine, and 2,5-Diflurorpyridine at Each Vacant Position”, J. Org. Chem., vol. 70, pp. 3039-3045 (2005).
Buback, M. et al., “Diastereoselectivity and Kinetics of Intermolecular Hetero Diels-Alder Reactions under High Pressure. A Significant Pressure-Induced Increase in Stereoselectivity”, Chem. Ber., vol. 122, pp. 1179-1186 (1989).
Canibano, V. et al., “Mild Regioselective Halogenation of Activated Pyridines withN-Bromosuccinimide”, Synthesis, vol. 14, pp. 2175-2179 (2001).
Capson, T., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, Dissertation, Dept Med Chem U of Utah, Abstract, Table of Contents, pp. 16,17,40-43,48-51, Summary (1987).
Carles, L. et al., “2-Pyridones from Cyanoacetamides and Enecarbonyl Compounds: Application to the Synthesis of Nothapodytine B”, J. Org. Chem., vol. 67, pp. 4304-4308 (2002).
Coffey, D. et al., “Six-Membered Ring Systems: Pyridines and Benzo Derivatives”, Progress in Heterocyclic Chemistry, vol. 14, pp. 257-278 (2002).
Coffey, D. et al., “Six-membered Ring Systems: Pyridines and Benzo Derivatives”, Progress in Heterocyclic Chemistry, vol. 13, pp. 238-260 (2001).
Colombo, G. et al., “Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR 141716”, Life Sciences, vol. 63(8), pp. PL 113-PL 117 (1998).
Comins, D et al., “Pyridines and their Benzo Derivatives: Reactivity at the Ring”, Comprehensive Heterocyclic Chemistry II, vol. 5, pp. 37-90 (1996).
Corey, E. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration that “Presqualene Pyrophosphate” is an Essential Intermediate on the Path to Squalene”, J. Amer. Chem. Soc., vol. 98(5), pp. 1291-1293 (1976).
Cottet, F. et al., “Three Chloro (trifluoromethyl) pyridines as Model Substrates for Regioexhaustive Functionalization”, Eur. J. Org. Chem., pp. 3793-3798 (2004).
Dennis, N., “Pyridines and their Benzo Derivatives: Reactivity of Substituents”, Comprehensive Heterocyclic Chemistry II, vol. 5, pp. 91-134 (1996).
Di Marzo, V. et al., “Leptin-regulated endocannabinoids are involved in maintaining food intake”, Nature, vol. 410, pp. 822-825 (2001).
Erian, A., “The Chemistry of β-Enaminonitriles as Versatile Reagents

Affiliated with

Also associated with

Rating

Triazolopyridine cannabinoid receptor 1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Triazolopyridine cannabinoid receptor 1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolopyridine cannabinoid receptor 1 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4052704